Serum-Based lncRNA ANRIL, TUG1, UCA1, and HIT Expressions in Breast Cancer Patients
Table 6
AUC curve for lncRNA ANRIL, TUG1, UCA1, and HIT with respect to different categories (lymph node involvement vs. noninvolvement, early vs. advanced stages of disease, distant organ metastases vs. without metastases).
With respect to lymph node involvement and noninvolvement
lncRNAs
AUC (95% CI)
Cut off
Sensitivity
Specificity
value
ANRIL
0.61 (0.50-0.72)
3.24
65%
52%
0.04
TUG1
0.52 (0.41-0.64)
6.79
56%
52%
0.62
UCA1
0.53 (0.40-0.63)
6.38
61%
54%
0.58
HIT
0.65 (0.55-0.76)
1.74
68%
58%
0.007
With respect to the early and advanced stages of disease
lncRNAs
AUC (95% CI)
Cut off
Sensitivity
Specificity
value
ANRIL
0.59 (0.48-0.70)
3.00
64%
53%
0.12
TUG1
0.61 (0.47-0.74)
5.93
72%
61%
0.06
UCA1
0.64 (0.52-0.76)
5.83
71%
58%
0.01
HIT
0.75 (0.65-0.84)
1.32
80%
50%
<0.0001
With respect to T2DM patients with respect to distant organ metastases and without metastases
